DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/0b813b/ulcerative_colitis) has announced the addition of GlobalData 's new report "Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global ulcerative colitis therapeutics market. The report identifies the key trends shaping and driving the global ulcerative colitis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ulcerative colitis sector.
The Ulcerative Colitis Therapeutics Market is forecast to Show Moderate Growth until 2018
GlobalData estimates that the global ulcerative colitis market was valued at $1.4billion in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 5.5% to reach $2.1billion by 2018. This growth forecast is primarily attributed to the currently approved drugs reaching their peak sales during the forecast period and secondarily due to the strong pipeline. Ulcerative Colitis Therapeutics Market, Global, Revenue and Forecasts ($bn), 2005-2018
GlobalData has found that the ulcerative colitis therapeutics market has low unmet need in the first line therapeutic segment, which implies that the market is well served by the current products in terms of efficacy and safety. However, unmet need exists for the second, third and fourth-line therapies, providing significant potential for new entrants in these segments.
Key Topics Covered:
1 List of Figures 2 Introduction 3 Ulcerative Colitis Therapeutics - Market Characterization 4 Ulcerative Colitis Therapeutics - Competitive Assessment 5 Ulcerative Colitis Therapeutics - Pipeline Assessment 6 Ulcerative Colitis Therapeutics - Clinical Trials Mapping 7 Ulcerative Colitis Therapeutics - Strategic Assessment 8 Ulcerative Colitis Therapeutics - Future Players 9 Ulcerative Colitis Therapeutics - Licensing and Partnership Deals 10 Ulcerative Colitis Therapeutics Market - Appendix
Companies Mentioned:
- Abbott Laboratories Cosmo Pharmaceuticals S.p.A Santarus, Inc. Centocor Ortho Biotech, Inc Takeda Pharmaceutical Company Limited
For more information visit http://www.researchandmarkets.com/research/0b813b/ulcerative_colitis